incorporated herein by reference. EC145 is used interchangeably with the term "conjugate" herein.

In one embodiment, a method of treatment of a cancer is provided. The method comprises administering EC145 in combination with one or more chemotherapeutic agents having a mode of action selected from microtubule disassembly inhibition and mitosis inhibition.


In another embodiment, the preceding method wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel (e.g., TAXOTERE™) and paclitaxel (e.g., TAXOL™ or ABRAXANE™) is described.

In another embodiment, use of EC145 in combination with one or more chemotherapeutic agents having a mode of action selected from the group consisting of microtubule disassembly inhibition and mitosis inhibition for the treatment of folate receptor expressing cancer cells is described.

In another embodiment, the use described above is provided wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel and paclitaxel.

In another embodiment, use of EC145 for the manufacture of a medicament for the treatment of folate receptor expressing cancer cells in combination with one or more chemotherapeutic agents having a mode of action selected from the group consisting of microtubule disassembly inhibition and mitosis inhibition is described.

In one aspect, there is provided the use of a compound of the formula




or a pharmaceutically acceptable salt thereof

in the manufacture of a medicament for the treatment of a non-small cell lung cancer in a patient, wherein the medicament is to be administered with a taxane.

In another embodiment, the use for manufacture of a medicament described above wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel and paclitaxel is described.

In one aspect, there is provided the use of a dose of a compound of the formula



or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of non-small cell lung cancer, wherein the medicament is to be administered to a patient in an intravenous bolus injection two days a week during weeks one and two of a three week cycle of therapy; and

wherein the medicament is to be administered with a dose of docetaxel over one hour on day one of the three week cycle of therapy.

In another embodiment, a pharmaceutical composition or combination comprising EC145 and one or more chemotherapeutic agents having a mode of action selected from the group consisting of microtubule disassembly inhibition and mitosis inhibition is described.

In another embodiment, the pharmaceutical composition or combination described in the preceding embodiment wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel and paclitaxel is described.

In another embodiment, a composition comprising EC145 and one or more chemotherapeutic agents having a mode of action selected from the group consisting of microtubule disassembly inhibition and mitosis inhibition for treating a cancer is described.

In another embodiment, the composition described in the preceding embodiment wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel and paclitaxel is described.

Several embodiments of the disclosure~~invention~~ are described by the following enumerated clauses:

1. A method of treatment of a cancer, the method comprising the step of administering EC145 in combination with one or more chemotherapeutic agents having a mode of action selected from the group consisting of microtubule disassembly inhibition and mitosis inhibition.

2. The method of clause 1 wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel and paclitaxel.

3. The method of clause 1 or 2 wherein the chemotherapeutic agent is docetaxel.

4. The method of clause 1 or 2 wherein the chemotherapeutic agent is paclitaxel.

5. Use of EC145 in combination with one or more chemotherapeutic agents having a mode of action selected from the group consisting of microtubule disassembly inhibition and mitosis inhibition for the treatment of folate receptor expressing cancer cells.

6. The use of clause 5 wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel and paclitaxel.

7. The use of clause 5 or 6 wherein the chemotherapeutic agent is docetaxel.

8. The use of clause 5 or 6 wherein the chemotherapeutic agent is paclitaxel.

9. Use of EC145 for the manufacture of a medicament for the treatment of folate receptor expressing cancer cells in combination with one or more chemotherapeutic agents having a mode of action selected from the group consisting of microtubule disassembly inhibition and mitosis inhibition.

10. The use of clause 9 wherein the one or more chemotherapeutic agents are selected from the group consisting of docetaxel and paclitaxel.

11. The use of clause 9 or 10 wherein the chemotherapeutic agent is docetaxel.

12. The use of clause 9 or 10 wherein the chemotherapeutic agent is paclitaxel.